Physicians' Academy for Cardiovascular Education

Clinical inertia in CKD - What is the rationale for SGLT2i?

Subtitling in English, German, Italian, Spanish and French

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - London, UK - Online CME

Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Video navigation menu

  • CKD is underdiagnosed in T2DM  01:53
  • Kidney outcomes in SGLT2i CV outcome trials 03:37
  • Cardiac benefits of SGLT2i in patients with CKD 05:31
  • Reno-protective effects of SGLT2i in people with T2DM and HFrEF 06:18
  • Diabetes guidelines and KDIGO guidelines  07:57
  • Conclusions 10:49

What is true about the outcomes of the EMPA-REG OUTCOME trial?

  • A. SGLT2i empagliflozin reduced kidney outcomes (evaluated as secondary outcomes) by 26%
  • B. Empagliflozin reduced time to CV death by 29% in patients with diabetes and prevalent kidney disease
  • C. The trial showed that empagliflozin has cardioprotective effects, but no reno-protective effects
Show the correct answer

Educational information

This lecture by Janaka Karalliedde was part of the EBAC-accredited symposium "SGLT2i in CKD: How to overcome clinical inertia?" held during the virtual ERA EDTA 2021 congress.


Janaka Karalliedde MD, PhD is a clinical senior lecturer in the School of Cardiovascular Medicine & Sciences at King's College London, and a consultant in diabetes, endocrinology and internal medicine at Guy’s and St Thomas’ Hospital London.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Podcast of this presentation Click here for the slides of the presentation


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: